TCGA-56-8624-01A-11R-2403-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.340
- PANCREAS_BETA_CELLS+0.340
- HEDGEHOG_SIGNALING+0.320
- KRAS_SIGNALING_DN+0.310
- UV_RESPONSE_DN+0.270
- APICAL_JUNCTION+0.200
- NOTCH_SIGNALING+0.200
- BILE_ACID_METABOLISM+0.180
- WNT_BETA_CATENIN_SIGNALING+0.150
- COAGULATION+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- E2F_TARGETS-0.540
- INTERFERON_GAMMA_RESPONSE-0.520
- MYC_TARGETS_V1-0.490
- UNFOLDED_PROTEIN_RESPONSE-0.480
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V2-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- DNA_REPAIR-0.430
- MTORC1_SIGNALING-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1396640 | GTEX | — | 0.931 |
| 2 | SRR1471350 | GTEX | — | 0.918 |
| 3 | C3L-01890 | — | cohortA2 | 0.907 |
| 4 | SRR8613714 | — | A | 0.895 |
| 5 | TCGA-44-6148-01A-11R-1755-07 | — | cohortA1 | 0.894 |
| 6 | TCGA-A7-A5ZX-01A-12R-A29R-07 | — | A | 0.891 |
| 7 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.889 |
| 8 | C3L-00444 | — | cohortA1 | 0.888 |
| 9 | SRR8613701 | — | A | 0.888 |
| 10 | SRR1331751 | GTEX | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.340 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.090 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |